Day One Biopharmaceuticals, Inc. (DAWN) Stock

About Day One Biopharmaceuticals, Inc.

Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.

Day One Biopharmaceuticals, Inc. is headquartered in US.

Day One Biopharmaceuticals, Inc. (DAWN) stock trades at $21.53 with a market capitalization of $2.22B. The stock is valued at a negative price-to-earnings (P/E) ratio of -20.70, reflecting a net loss over the last twelve months, price-to-book of 5.05, price-to-sales of 14.06. Over the past 52 weeks the stock has ranged between $5.64 and $21.53, and currently trades at or near its 52-week high.

On profitability, Day One Biopharmaceuticals, Inc. generates a return on equity (ROE) of -23.43% (negative, reflecting a net loss), return on capital employed of -28.56%, an operating margin of -80.76%, a net profit margin of -67.85%.

Official website: dayonebio.com

Day One Biopharmaceuticals, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Day One Biopharmaceuticals, Inc. reported revenue of $0 rising to $158.0M. Compounded, revenue has grown —% a year over five years, —% over three, 20.6% over the last twelve months. Net profit fell to $-107.0M.

The most recent net margin is -67.85%. On a trailing twelve-month basis to Dec '25, revenue is $159.0M and net profit $-107.0M.

Borrowings stand at $3.0M, cash on hand is $441.1M, cash from operations was $-104.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -33.1% over five years, and was -24.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Day One Biopharmaceuticals, Inc. (DAWN) — frequently asked questions